Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Contezolid in Mycobacterium Abscessus Infections
NCT07372781Phase 2Enrolling by invitation
- Sponsor
- Beijing Chest Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of contezolid in Mycobacterium abscessus infection (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Time To Positivity in sputum cultures at 14 days. Started Jan 2026; status: enrolling by invitation.
02
Drugs
contezolid
03
Conditions
Mycobacterium abscessus infection
Beyond the preview
Go deeper on NCT07372781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07372781.